In 2014, FDA gave pembrolizumab accelerated approval for melanoma.?
Today, the 3-year survival rate in melanoma patients is reported to be 40%.? ASCO president Dr. Julie Vose told NBC News, “This is something really different than what we have seen in the past.” ?nbcnews.to/25btTBv? via @nbcnews? @3SixtyPharma
3SixtyPharma Alzheimer's Anti-IgE anti-inflammatory anti-TNF anti-TNF-? B-cell Biosimilar clinical clinical research CNS Communication CT-P13 DEMENTIA FDA gastrointestinal genome GI Inflammation Inflectra infliximab interchangeability investigational JAK inhibitor KTE-C19 Lymphoma oncology patients Pharma Portfolio Management Program Management Project Management rare disease remote Remsima rheumatoid arthritis spondyloarthritis switching Theravance Biopharma virtual w webinar White House White House Office of Management and Budget White House OMB
